journal
MENU ▼
Read by QxMD icon Read
search

Clinical & Translational Oncology

journal
https://www.readbyqxmd.com/read/29340974/inhibiting-6-phosphogluconate-dehydrogenase-selectively-targets-breast-cancer-through-ampk-activation
#1
Xiaoyu Yang, Xiaochun Peng, Jiangrong Huang
PURPOSE: 6-phosphogluconate dehydrogenase (6PGD), a key enzyme of the oxidative pentose phosphate pathway, is involved in tumor growth and metabolism. Although high 6PGD activity has been shown to be associated with poor prognosis, its role and therapeutic value in breast cancer remain unknown. METHODS: The levels and roles of 6PGD were analyzed in breast cancer cells and their normal counterparts. The underlying mechanisms of 6PGD's roles are also analyzed. RESULTS: We found that 6PGD is aberrantly activated in breast cancer as shown by its increased transcriptional and translational levels as well as enzyme activity in breast cancer tissues and cell lines compared to normal counterparts...
January 16, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29335830/from-imaging-to-biology-of-glioblastoma-new-clinical-oncology-perspectives-to-the-problem-of-local-recurrence
#2
REVIEW
A Zygogianni, M Protopapa, A Kougioumtzopoulou, F Simopoulou, S Nikoloudi, V Kouloulias
GBM is one of the most common and aggressive brain tumors. Surgery and adjuvant chemoradiation have succeeded in providing a survival benefit. Although most patients will eventually experience local recurrence, the means to fight recurrence are limited and prognosis remains poor. In a disease where local control remains the major challenge, few trials have addressed the efficacy of local treatments, either surgery or radiation therapy. The present article reviews recent advances in the biology, imaging and biomarker science of GBM as well as the current treatment status of GBM, providing new perspectives to the problem of local recurrence...
January 15, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29335829/pancreaticoduodenectomy-for-periampullary-tumours-a-review-article-based-on-surveillance-end-results-and-epidemiology-seer-database
#3
REVIEW
S K Kamarajah
INTRODUCTION: This study set to examine relative survival of patients with periampullary cancers undergoing pancreaticoduodenectomy (PD). METHODS: Using the Surveillance, End Results and Epidemiology (SEER) database, this study identified 9877 patients with non-metastatic pancreatic adenocarcinoma who underwent PD between 2004 and 2013. RESULTS: Ampullary carcinomas have the best survival among periampullary malignancies. Lymph node ratio is a significant prognostic factor, even when stratified by tumour types...
January 15, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29327241/a-suvmax-based-propensity-matched-analysis-of-stereotactic-body-radiotherapy-versus-surgery-in-stage-i-non-small-cell-lung-cancer-unveiling-the-role-of-18f-fdg-pet-ct-in-clinical-decision-making
#4
L Ye, F Xu, S Shi, Z Zeng, X Jin, Y Huang, C Lu, J Gu, D Ge, J He
BACKGROUND: The value of maximum standard uptake value (SUVmax) was overlooked in current studies comparing stereotactic body radiotherapy (SBRT) versus surgery for stage I non-small cell lung cancer (NSCLC). Herein, we aimed to compare the 3-year outcomes based on patients for whom SUVmax were available, and to explore the role of SUVmax in clinical decision-making. METHODS: From January 2010 to June 2016, data of eligible patients were collected. Patient variables and clinical outcomes were compared in both unmatched and matched groups using propensity score matching (PSM)...
January 11, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29318449/reduction-oxidation-redox-system-in-radiation-induced-normal-tissue-injury-molecular-mechanisms-and-implications-in-radiation-therapeutics
#5
REVIEW
R Yahyapour, E Motevaseli, A Rezaeyan, H Abdollahi, B Farhood, M Cheki, S Rezapoor, D Shabeeb, A E Musa, M Najafi, V Villa
Every year, millions of cancer patients undergo radiation therapy for treating and destroying abnormal cell growths within normal cell environmental conditions. Thus, ionizing radiation can have positive therapeutic effects on cancer cells as well as post-detrimental effects on surrounding normal tissues. Previous studies in the past years have proposed that the reduction and oxidation metabolism in cells changes in response to ionizing radiation and has a key role in radiation toxicity to normal tissue. Free radicals generated from ionizing radiation result in upregulation of cyclooxygenases (COXs), nitric oxide synthase (NOSs), lipoxygenases (LOXs) as well as nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), and their effected changes in mitochondrial functions are markedly noticeable...
January 9, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29313208/perspective-on-immune-oncology-with-liquid-biopsy-peripheral-blood-mononuclear-cells-and-microbiome-with-non-invasive-biomarkers-in-cancer-patients
#6
REVIEW
A Mitsuhashi, Y Okuma
Antibodies against immune checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) and anti-programmed death ligand 1 (PD-L1) play a key role in the treatment of advanced lung cancer. To examine the clinical benefits of these agents, preclinical and clinical studies have been conducted to identify definitive biomarkers associated with cancer status. Analysis of the blood and feces of tumor patients has attracted attention in recent studies attempting to identify non-invasive biomarkers such as cytokines, soluble PD-L1, peripheral blood mononuclear cells, and gut microbiota...
January 8, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29313207/survey-on-paediatric-tumour-boards-in-europe-current-situation-and-results-from-the-expo-r-net-project
#7
A Juan Ribelles, P Berlanga, G Schreier, M Nitzlnader, B Brunmair, V Castel, S Essiaf, A Cañete, R Ladenstein
BACKGROUND: Under the ExPO-r-NeT project (European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment), we aimed to identify paediatric oncology tumour boards in Europe to investigate the kind of technologies and logistics that are in place in different countries and to explore current differences between regions. METHODS: A 20-question survey regarding several features of tumor boards was designed. Data collected included infrastructure, organization, and clinical decision-making information from the centres...
January 8, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29305743/correction-to-seom-clinical-guidelines-for-the-treatment-of-metastatic-prostate-cancer-2017
#8
J Cassinello, J Á Arranz, J M Piulats, A Sánchez, B Pérez-Valderrama, B Mellado, M Á Climent, D Olmos, J Carles, M Lázaro
The original article shows two mistakes, which are listed here.
January 5, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29305742/cxcl12-gene-silencing-down-regulates-metastatic-potential-via-blockage-of-mapk-pi3k-ap-1-signaling-pathway-in-colon-cancer
#9
J Ma, H Su, B Yu, T Guo, Z Gong, J Qi, X Zhao, J Du
BACKGROUND: To investigate the effect of CXCL12 gene silencing on proliferation,invasion, angiogenesis and the relationship of MAPK/PI3K/AP-1 signaling pathway in colon cancer cells. METHODS: RT-PCR and Western-blot were used to detect the expression of CXCL12 mRNA and protein in four colon cancer cell lines. Human colon cancer cells were transfected with CXCL12 siRNA carrying by Lipofectamine 2000. The expression of CXCL12 protein was confirmed by immunoblotting...
January 5, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29294225/correction-to-recommendations-for-the-follow-up-care-of-female-breast-cancer-survivors-a-guideline-of-the-spanish-society-of-medical-oncology-seom-spanish-society-of-primary-care-physicians-semergen-spanish-society-for-family-and-community-medicine-semfyc-spanish
#10
https://www.readbyqxmd.com/read/29273958/biomarkers-in-breast-cancer-a-consensus-statement-by-the-spanish-society-of-medical-oncology-and-the-spanish-society-of-pathology
#11
R Colomer, I Aranda-López, J Albanell, T García-Caballero, E Ciruelos, M Á López-García, J Cortés, F Rojo, M Martín, J Palacios-Calvo
This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy...
December 22, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29273957/oncological-strategies-for-locally-advanced-rectal-cancer-with-synchronous-liver-metastases-interval-strategy-versus-rectum-first-strategy-a-comparison-of-short-term-outcomes
#12
H Salvador-Rosés, S López-Ben, M Casellas-Robert, P Planellas, N Gómez-Romeu, R Farrés, E Ramos, A Codina-Cazador, J Figueras
BACKGROUND: The goal of treatment for patients with synchronous liver metastases (SLM) from rectal cancer is to achieve a complete resection of both tumor locations. For patients with symptomatic locally advanced rectal cancer with resectable SLM at diagnosis, our usual strategy has been the rectum first approach (RF). However, since 2014, we advocate for the interval approach (IS) that involves the administration of chemo-radiotherapy followed by the resection of the SLM in the interval of time between rectal cancer radiation and rectal surgery...
December 22, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29256155/adjuvant-concurrent-chemoradiation-therapy-in-patients-with-microscopic-residual-tumor-after-curative-resection-for-extrahepatic-cholangiocarcinoma
#13
J Lee, S H Kang, O K Noh, M Chun, Y-T Oh, B-W Kim, S-W Kim
PURPOSE: We investigated the role of adjuvant concurrent chemoradiation therapy (CCRT) in patients with a microscopically positive resection margin (R1) after curative resection for extrahepatic cholangiocarcinoma (EHCC). METHODS/PATIENTS: A total of 84 patients treated with curative resection for EHCC were included. Fifty-two patients with negative resection margins did not receive any adjuvant treatments (R0 + S group). The remaining 32 patients with microscopically positive resection margins received either adjuvant CCRT (R1 + CCRT group, n = 19) or adjuvant radiation therapy (RT) alone (R1 + RT group, n = 13)...
December 18, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29256154/seom-seram-semnim-guidelines-on-the-use-of-functional-and-molecular-imaging-techniques-in-advanced-non-small-cell-lung-cancer
#14
G Fernández-Pérez, R Sánchez-Escribano, A M García-Vicente, A Luna-Alcalá, J Ceballos-Viro, R C Delgado-Bolton, J C Vilanova-Busquets, P Sánchez-Rovira, M P Fierro-Alanis, R García-Figueiras, J E Alés-Martínez
Imaging in oncology is an essential tool for patient management but its potential is being profoundly underutilized. Each of the techniques used in the diagnostic process also conveys functional information that can be relevant in treatment decision-making. New imaging algorithms and techniques enhance our knowledge about the phenotype of the tumor and its potential response to different therapies. Functional imaging can be defined as the one that provides information beyond the purely morphological data, and include all the techniques that make it possible to measure specific physiological functions of the tumor, whereas molecular imaging would include techniques that allow us to measure metabolic changes...
December 18, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29243075/the-effect-of-aspirin-on-circulating-tumor-cells-in-metastatic-colorectal-and-breast-cancer-patients-a-phase-ii-trial-study
#15
L Yang, Z Lv, W Xia, W Zhang, Y Xin, H Yuan, Y Chen, X Hu, Y Lv, Q Xu, X Weng, C Ni
PURPOSE: Aspirin could reduce the risk of cancer metastasis. Circulating tumor cells (CTCs) are a key factor of cancer metastasis, but no evidence has revealed how aspirin affects CTCs and its epithelial-mesenchymal transition (EMT). Here, we conducted a clinical trial to investigate how aspirin affects CTCs in metastatic colorectal cancer (MCC) and breast cancer patients (MBC). METHODS: The trial is retrospective registered at clinicaltrials.gov (NCT02602938). The eligible patients are given 100 mg aspirin q...
December 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29243074/predictive-factors-and-the-important-role-of-detectable-prostate-specific-antigen-for-detection-of-clinical-recurrence-and-cancer-specific-mortality-following-robot-assisted-radical-prostatectomy
#16
S García-Barreras, F Rozet, I Nunes-Silva, V Srougi, R Sanchez-Salas, E Barret, M Galiano, X Cathelineau
PURPOSE: To evaluate predictive factors associated with detectable prostate-specific antigen (PSA) and describe clinical recurrence (CR) and cancer-specific mortality (CSM) after robot-assisted radical prostatectomy (RARP). METHODS: The study included 2500 patients who were treated with RARP at a single institution between 2000 and 2016. All patients had clinically localized PCa. Patients were divided into two groups according to PSA value at 6 weeks after surgery: undetectable (n = 2271; PSA < 0...
December 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29238915/seom-clinical-guidelines-for-endometrial-cancer-2017
#17
A Santaballa, X Matías-Guiu, A Redondo, N Carballo, M Gil, C Gómez, M Gorostidi, M Gutierrez, A Gónzalez-Martín
Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment...
December 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29327240/geriatric-oncology-in-spain-survey-results-and-analysis-of-the-current-situation
#18
R Gironés, I Morilla, C Guillen-Ponce, M D Torregrosa, I Paredero, E Bustamante, S Del Barco, G Soler, B Losada, L Visa, E Llabrés, B Fox, J L Firvida, R Blanco, M Antonio, F Aparisi, M Pi-Figueras, E Gonzalez-Flores, M J Molina-Garrido, J Saldaña
INTRODUCTION: Geriatric oncology (GO) is a discipline that focuses on the management of elderly patients with cancer. The Spanish Society of Medical Oncology (SEOM) created a Working group dedicated to geriatric oncology in February 2016. OBJECTIVES: The main goal of this study was to describe the current situation in Spain regarding the management of elderly cancer patients through an online survey of medical oncologists. METHODS: A descriptive survey was sent to several hospitals by means of the SEOM website...
December 11, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29230693/clinical-implications-of-the-deregulated-tp73-isoforms-expression-in-cancer
#19
REVIEW
N Rodríguez, A Peláez, R Barderas, G Domínguez
TP73 is a member of the TP53 family whose expression has been observed altered in most human cancers and associated with the prognosis. TP73 translates into a complex number of isoforms with both oncogenic and tumour-suppressor functions and presents a complex cross-talk with other members of the family (TP53 and TP63). In this revision, we focus on the evidence that may support TP73 variants as prognostic markers in cancer. Nowadays, most publications in this topic highlight the association between overexpression of the oncogenic variants and failure to respond to chemotherapy and/or shorter survival...
December 11, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29230692/seom-clinical-guideline-on-unknown-primary-cancer-2017
#20
F Losa, G Soler, A Casado, A Estival, I Fernández, S Giménez, F Longo, R Pazo-Cid, J Salgado, M Á Seguí
Cancer of unknown primary site is a histologically confirmed cancer that manifests in advanced stage, with no identifiable primary site following standard diagnostic procedures. Patients are initially categorized based on the findings of the initial biopsy: adenocarcinoma, squamous-cell carcinoma, neuroendocrine carcinoma, and poorly differentiated carcinoma. Appropriate patient management requires understanding several clinical and pathological features that aid in identifying several subsets of patients with more responsive tumors...
December 11, 2017: Clinical & Translational Oncology
journal
journal
41053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"